New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 6, 2013
04:55 EDTALNY, ALNY, ALNY, ALNY, ALNY, ALNY, ALNY, MDCO, MDCO, MDCO, MDCO, MDCO, MDCO, MDCO, PRGO, PRGO, PRGO, PRGO, PRGO, PRGO, PRGO, TSRO, TSRO, TSRO, TSRO, TSRO, TSRO, TSRO, MGNX, MGNX, MGNX, MGNX, MGNX, MGNX, MGNX, RGEN, RGEN, RGEN, RGEN, RGEN, RGEN, RGEN, ACT, ACT, ACT, ACT, ACT, ACT, ACT, BMY, BMY, BMY, BMY, BMY, BMY, BMY, ENDP, ENDP, ENDP, ENDP, ENDP, ENDP, ENDP, GSK, GSK, GSK, GSK, GSK, GSK, GSK, MRK, MRK, MRK, MRK, MRK, MRK, MRK, NVS, NVS, NVS, NVS, NVS, NVS, NVS, SHPG, SHPG, SHPG, SHPG, SHPG, SHPG, SHPGFBN Securities to host a bus tour
5th Semi-Annual Silicon Valley Technology Bus Tour visits companies throughout the Silicon Valley on December 6-12.
News For SHPG;NVS;MRK;GSK;ENDP;BMY;ACT;RGEN;MGNX;TSRO;PRGO;MDCO;ALNY From The Last 14 Days
Check below for free stories on SHPG;NVS;MRK;GSK;ENDP;BMY;ACT;RGEN;MGNX;TSRO;PRGO;MDCO;ALNY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
April 15, 2014
07:22 EDTNVS, SHPGNovartis to Shire said to mull offers for ThromboGenics, Bloomberg says
Subscribe for More Information
06:36 EDTNVSRanbaxy inspection failures add $900M to heart drug costs, Bloomberg says
A gap in U.S. patent law has kept cheap copies of Novartis' (NVS) heart drug Diovan off the market for 18 months, which has cost U.S. consumers and insurers as much as $900M in possible savings, reported Bloomberg. Ranbaxy (RBXLY) is the only company permitted to sell a generic version of Diovan, and hasnít been able to manufacture and market them after four factories it runs in India failed U.S. inspections. Reference Link
06:32 EDTNVS, MRK, BMY, GSKPatients paying much more for specialty drugs, NY Times says
The amount that patients with certain diseases must pay for specialty drugs has increased significantly, a research firm reported, according to The New York Times. Meanwhile, consumers' use of health care increased in 2013 for the firm time in three years, the newspaper quoted the firm, the IMS Institute for Healthcare Informatics, as saying. Publicly traded drug makers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Publicly traded health insurers include AMERIGROUP (AGP), Aetna (AET), Centene (CNC), Cigna (CI), Health Net (HNT), Healthspring (HS), Humana (HUM), Molina Healthcare (MOH), UnitedHealth (UNH), WellCare (WCG) and WellPoint (WLP).Reference Link
06:30 EDTRGENRepligen initiated with a Buy at Jefferies
Subscribe for More Information
April 14, 2014
18:00 EDTMRKU.S. FDA approves Merck's GRASTEK
Subscribe for More Information
14:42 EDTALNY, NVSAlnylam slips after Novartis reportedly cuts back RNAi development
Subscribe for More Information
11:48 EDTNVSNovartis significantly reducing RNAi development efforts, FierceBiotech says
Subscribe for More Information
08:15 EDTBMYBristol-Myers submits NDA for Reyataz-cobicistat combo for HIV-1
Bristol-Myers Squibb (BMY) announced the submission of a new drug application, or NDA, on April 4 to the FDA for a fixed-dose combination of atazanavir sulfate, a protease inhibitor marketed as Reyataz, and cobicistat, an investigational pharmacokinetic enhancer, or boosting agent, that can increase the level of certain HIV-1 medicines in the blood and make them more effective. Bristol-Myers Squibb is seeking approval of the fixed-dose combination tablet for use in combination with other antiretroviral agents for the treatment of HIV-1 infection. If approved, atazanavir sulfate and cobicistat could offer patients living with HIV-1 a single tablet that eliminates the need to take a boosting agent in a separate tablet. Cobicistat is being developed by Gilead Sciences (GILD). Under the terms of a previously announced agreement, Bristol-Myers Squibb and its affiliates are responsible for the formulation, manufacturing, registration, distribution and commercialization of the atazanavir sulfate and cobicistat fixed-dose combination product worldwide. Gilead retains sole rights for the manufacture, development and commercialization of cobicistat as a stand-alone product and for use in combination with other agents.
06:40 EDTGSKGlaxoSmithKline paid bribes to Polish doctors to promote Seretide, BBC says
Subscribe for More Information
06:08 EDTMRKMerck volatility elevated into Q1 and outlook
Subscribe for More Information
April 11, 2014
10:30 EDTACTActavis and Mylan shares recommended at Bernstein
07:50 EDTMGNXMacroGenics management to meet with Leerink
Subscribe for More Information
05:22 EDTMRKMerck says Hepatitis C combination therapy shows antiviral activity
Subscribe for More Information
April 10, 2014
17:44 EDTMRKMerck stock could return 20%, Barron's says
Subscribe for More Information
11:42 EDTGSKReport claims Tamiflu, Relenza do little to prevent the spread of flu
Subscribe for More Information
09:37 EDTMRKActive equity options trading on open
Active equity options trading on open according to Track Data: SIRI RAD AAPL AMZN AA FB TSLA MRK CVX C
09:21 EDTMRKOn The Fly: Pre-market Movers
Subscribe for More Information
08:03 EDTMRKXencor Merck receives milestone payment from Merck for using XmAb antibody
Xencor (XNCR) announced that the company has received a milestone payment from Merck (MRK), through a subsidiary, triggered by the initiation of a Phase 1 clinical trial for an undisclosed biologic drug candidate that uses Xencor's XmAb antibody engineering intellectual property. Under the terms of the agreement signed in June 2013, Xencor granted Merck a non-exclusive license to certain Xencor patents for use in an undisclosed product, as well as an option to license the same intellectual property for future products. Xencor received an upfront payment and continues to receive annual maintenance fees. Xencor is also eligible to receive milestone payments associated with the successful development of Merck product candidates, as well as royalties on sales of any potential products that may result from this agreement.
07:04 EDTBMYBristol-Myers presents Phase III data on all-oral Daclatasvir and Asunaprevir
Subscribe for More Information
05:27 EDTMRKMerck announces data from C-WORTHy study
Merck announced additional data from the ongoing C-WORTHy study, a multi-arm Phase 2 clinical trial evaluating the efficacy and safety of a once-daily, all-oral regimen combining MK-5172, an investigational hepatitis C virus, or HCV, NS3/4A protease inhibitor, and MK-8742, an investigational HCV NS5A replication complex inhibitor, among patients with chronic HCV Genotype 1 infection, or GT1. In an interim analysis of treatment-naÔve, non-cirrhotic patients administered a 12-week regimen of MK-5172/MK-8742, with and without ribavirin, or RBV, a sustained viral response, or SVR, was observed in 98% of patients administered MK-5172/MK-8742 alone and 94% in those administered MK-5172/MK-8742 plus RBV.
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use